Journal of Otolaryngology Advances · Current Issue
Current Issue of the Journal of Otolaryngology Advances
The journal publishes in numbered volumes and issues. Volume 2, Issue 4 is the current issue. Every record below is stated with its type, its authors, its pages, its date and its identifier.
Volume 2, Issue 4 3 records ISSN 2379-8572 Crossref DOI prefix 10.14302
The current issue
The Journal of Otolaryngology Advances publishes in numbered volumes and issues. Each record is assigned to one issue, paginated continuously within it, and deposited with that volume and issue in its metadata, so an article can be cited by volume, issue and page in the ordinary way.
- Current issue
- Volume 2, Issue 4
- Records in this issue
- 3
- Issues published
- 8, listed in the archive with every article they contain.
- Identifiers
- Registered articles carry a Crossref DOI under the prefix 10.14302. A record is shown with its DOI only where that DOI is registered and resolves; otherwise it is shown with its page on the journal.
- Access
- Every article is open access from the day it appears, published under the Creative Commons Attribution 4.0 license with copyright retained by the authors.
In this issue
Volume 2, Issue 4
3 records, in issue order
Publication notice
Issued by the Editor-in-Chief on behalf of the Journal of Otolaryngology Advances.
Retracts
Publication notice
Issued by the Editor-in-Chief on behalf of the Journal of Otolaryngology Advances.
Use of Stem Cell Growth and Differentiation Factors (Scdsf) in Central Vertigo
Pisano Gianpaolo, Spaggiari Piergiorgio, Pintucci Jean Pierre, Blanco Massimo, Tribbia Caterina, Liberati Chiara, Bonis Teodosio De, Grappeggia Giorgia, Biava Pier Mario
Abstract
The clinical use of SCDSF factors in neuro-degenerative pathologies offers a potential therapeutic opportunity. Our observational study aims to evaluate its efficacy in patients affected by Central Vertigo1.
A case series divided into two subgroups, all affected by non-migrainous central vertigo, was selectively subjected, in epigenetic terms versus the genome, to the administration of SCDSF with a regenerative action or to the administration of a reprogramming and then regenerative action. The cohort was divided into two groups due to the emergence of a resistance to the action of neuro-regenerative SCDSF when administered individually according to consolidated therapy schemes. To recover efficacy, it became necessary to first administer reprogramming SCDSF and only subsequently the neuro-regenerative SCDSF.
The observation that a therapeutic barrier was overcome during the study—a barrier to the action of neuro-regenerative SCDSF, only when preceded by the administration of reprogramming SCDSF versus the genome—highlighted a deeper mechanism. A targeted action aimed at recovering the functionality of the epigenetic code was employed to counteract environmental epi-genotoxicity.
Where to read further
-
Archive
Every issue the journal has published, with its articles and identifiers.
-
Aims and Scope
What the journal publishes, and the boundary a manuscript has to sit inside.
-
Editorial board
The editors who assess submissions and take the decisions on them.
-
Editorial policies
Ethics, integrity, corrections and retractions in full.
-
About the journal
What the journal is, who it serves, and the principles it publishes under.
-
Instructions for authors
How a manuscript must be prepared and reported before it reaches an editor.
The published record
Corrections and retractions are published as citable records in their own right and are listed here with the article each one concerns, so the record of what the journal has published stays complete.
Journal of Otolaryngology Advances (JOA)
ISSN 2379-8572 · Crossref DOI prefix 10.14302 · Published by Open Access Pub ·
Articles are published under CC BY 4.0 with copyright retained by the authors.